Hans Guehring

This inventor holds 17 USPTO granted patents and 16 published patent applications, plus 5 CIPO patents and 15 EPO patents, primarily in Biomarkers Research. Top assignees: Merck Patent Gmbh, Ablynx N.v., Sanofi. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans Guehring. Retrieved from https://idiyas.com/inventor/hans-guehring

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 16)

% Patents Active = 76.5

CIPO Patents = 5 (Patent Applications = 13)

EPO Patents = 15 (Patent Applications = 21)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 26(Granted Patents)

Location History:

Eltville, DE (2013 - 2018)
Geisenheim, DE (2022)
Geissenheim, DE (2022 - 2023)

Company Filing History:

Sanofi-A Ventis Deutschland Gmbh

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

Areas of Expertise:

Osteoarthritis

FGF-18

Biomarkers

Immunoglobulins

ADAMTS

MMP13

Polypeptides

Aminostatin

Pain Treatment

Dosing Regimen

Enrichment Strategies

Intraarticular Application

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12383603 - Markers useful in enrichment strategies for the treatment of osteoarthritis (2025-08-12),

2. 12332251 - Metabolic biomarkers for predicting responsiveness to FGF-18 compound (2025-06-17),

3. 12332250 - Inflammatory biomarkers for predicting responsiveness to FGF-18 compound (2025-06-17),

4. 12209136 - ADAMTS binding immunoglobulins (2025-01-28),

5. 12129308 - MMP13 binding immunoglobulins (2024-10-29),

6. 11813307 - Polypeptides binding ADAMTS5, MMP13 and aggrecan (2023-11-14),

7. 11513128 - Metabolic biomarkers for predicting responsiveness to FGF-18 compound (2022-11-29),

8. 11467169 - Inflammatory biomarkers for predicting responsiveness to FGF-18 compound (2022-10-11),

9. 11261260 - ADAMTS binding immunoglobulins (2022-03-01),

10. 10086112 - Implant comprising FGF-18 (2018-10-02),

11. 9889179 - FGF-18 compound dosing regimen (2018-02-13),

12. 9839665 - Aminostatin derivatives for the treatment of arthrosis (2017-12-12),

13. 9750784 - Intraarticular application of pepstatin in the case of arthrosis (2017-09-05),

14. 9724388 - FGF-18 compound dosing regimen (2017-08-08),

15. 9345742 - Aminostatin derivatives for the treatment of arthrosis (2016-05-24),

Title: Innovations by Hans Guehring: A Profile of a Visionary Inventor

Introduction

Hans Guehring, a distinguished inventor based in Eltville, Germany, has made significant contributions to the field of biomedical research. With a remarkable portfolio of 14 patents, he has been a driving force behind innovative technologies aimed at therapeutic advancements.

Latest Patents

Among his most notable inventions are immunoglobulins designed to bind to specific proteins, showcasing his expertise in therapeutic applications. One of his latest patents involves ADAMTS binding immunoglobulins, which relate to immunoglobulins that bind ADAMTS5. He has developed polypeptides that either comprise or consist of these immunoglobulins. This invention extends to various constructs, such as immunoglobulin single variable domains (ISVDs) and nucleic acids encoding these immunoglobulins. The applications of this invention are significant, particularly in pharmaceutical compositions aimed at prophylactic and therapeutic purposes.

Another significant patent by Guehring is related to MMP13 binding immunoglobulins. This invention focuses on immunoglobulins that specifically bind MMP13, leading to polypeptides and nucleic acids encoding these polypeptides. His innovations in this area provide methods for preparing such polypeptides and encompass pharmaceutical compositions that can be utilized for prophylactic, therapeutic, or diagnostic purposes, particularly emphasizing the inhibition of MMP13 activity.

Career Highlights

Hans Guehring has held positions at notable companies, including Merck Patent GmbH and Ablynx N.V. His work in these organizations has allowed him to further refine his inventions and contribute to the advancement of biomedical therapies.

Collaborations

Throughout his career, Guehring has collaborated with esteemed colleagues such as Christoph Hubertus Ladel and Sven Lindemann. These partnerships have played a significant role in enhancing the scope and impact of his research and inventions.

Conclusion

Hans Guehring stands out as a prominent figure in the innovation landscape of biomedical research. His extensive body of work, characterized by cutting-edge patents and collaborative endeavors, underscores his commitment to developing transformative therapeutic solutions. As he continues to push the boundaries of science, his contributions are poised to make a lasting impact in the medical field.

Profile summary based on public USPTO records.